Drug
Biib 722 CL
Biib 722 CL: highest development phase Phase 1, developed by Boehringer Ingelheim. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| BIIB 722 CL solution NCT02227030 | Phase 1 | Healthy |
Latest
No recent events.
Follow Biib 722 CL on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.